Mechanistic Basis of Dual Checkpoint Inhibition: Targeting PD-1 and LAG-3 Pathways

Emerging evidence demonstrates that dual checkpoint inhibition targeting PD-1 and LAG-3 pathways can synergistically restore anti-tumor immunity, offering a strong scientific rationale for combination strategies such as nivolumab + relatlimab. To explore the mechanistic foundations and clinical relevance of dual checkpoint blockade, Bristol Myers Squibb ® , India invites you to an exclusive session under the lecture series “ Reimagine Melanoma Care: Unlocking Novel IO pathway with LAG-3 & PD-1 Blockade .” Join expert Oncologist Dr. Prabhat Bhargava for session 2 on “ Mechanistic Basis of Dual Checkpoint Inhibition: Targeting PD-1 and LAG-3 Pathways .” on Saturday, 9th May 2026 , from 7:00 PM to 8:00 PM IST.

Don’t Miss This Insightful Session! ##DISCLAIMER## The content provided on Docplexus is intended for educational purposes only. While we strive to ensure its accuracy, we make no…